

Remarks

Claims 8-14 and 17-25 are canceled, and claims 1-7, 15 and 16 are pending.

Rejection of claims 8-14 & 21-25 under 35 U.S.C. §102(b)

Examiner has rejected claims 8-14 & 21-25 as being anticipated by US6,166,063. As these claims are canceled, the rejection is rendered moot.

Rejection of claims 8, 9 and 17 under 35 U.S.C. §112, 2<sup>nd</sup> paragraph

Examiner has rejected claims 8, 9 and 17 as being indefinite. As these claims are canceled, the rejection is rendered moot.


Rejection of claims 8-14 & 21-25 under obviousness-type double patenting

Examiner has rejected claims 8-14 & 21-25 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of US6,166,063. As these claims are canceled, the rejection is rendered moot.

In view of the above, applicant submits that all issues raised in the Office Action have been addressed herein. Examiner has indicated that claims 1-7, 15 and 16 are in condition for allowance, applicant respectfully requests allowance of these claims.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-9276

  
Cynthia Zhang  
Attorney for Applicants  
Reg. No. 53,827

Date: 12/20/2007